Menu
Washingtoner
  • Home
  • Health
  • Artificial Intelligence
  • Technology
  • Entertainment
  • Software
  • Business
  • Education
  • Real Estate
Washingtoner

Stuart Therapeutics, Inc. Announces Upcoming Presentations at ARVO 2024
Washingtoner/10255123

Trending...
  • Green Revolution CBD Spotlights Its Water-Soluble Focus Tincture With CBD, CBG and Lion's Mane
  • Tacoma: Applicants Sought for the Bicycle Pedestrian Technical Advisory Group
  • Tacoma: Closures Projected to Allow for Arterial Work
STUART, Fla., April 19, 2024 ~ Stuart Therapeutics, Inc., a clinical-stage ophthalmic biopharmaceutical company, is making strides in the development of therapies for various eye disorders. The company's President and CEO, Eric Schlumpf, will be presenting their latest research results at two upcoming meetings in early May.

On Friday, May 3rd, Schlumpf will be speaking at the Dry Horizons Symposium, co-sponsored by Ora, Inc. His presentation will focus on Stuart Therapeutics' innovative dry eye disease program, which is currently in a Phase 3 trial. The following day, Saturday May 4th, he will be presenting the company's latest pre-clinical results in retinitis pigmentosa and exudative retinal indications at the Ophthalmology Innovation Source (OIS) Retina Meeting.

Both of these meetings will take place at the Four Seasons Hotel in Seattle, Washington. This provides an opportunity for Stuart Therapeutics to showcase their groundbreaking research to a wide audience of industry professionals.

More on Washingtoner
  • Matt Zavala of Zavala Law, PC Elected to Ventura County Bar Association Board of Directors
  • Montana Artist Ryan Jolley Receives Goodman Award at Mountain Oyster Club Art Show
  • Make Your Move to Luxury Living at Heritage at Hopewell with Rates Starting at Just 3.750% (5.803% APR)
  • Scott Glickson Joins STS Capital Partners as Managing Director
  • Spokane: City Closures Planned for the Thanksgiving Holiday

In addition to Schlumpf's presentations, members of Stuart Therapeutics' R&D team have also co-authored a poster presentation that will be presented by researchers from the University of Rochester at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting from May 5-9, 2024. The poster presentation titled "Scleral collagen remodeling and repair assessed in intact eyes through Second Harmonic Generation" focuses on work done at the University of Rochester using Stuart Therapeutics' proprietary collagen mimetic peptide platform. This research aims to understand its effectiveness in reversing scleral collagen disruption in the eye, which is believed to contribute to myopia.

The study authors include Aldo Tecse, Kaitlin Wozniak, James German, Alex McMullen, Mark Buckley, Robert Baratta, Eric Schlumpf, Brian J. Del Buono, Michael Telias and Susana Marcos. This collaboration between Stuart Therapeutics and the University of Rochester highlights the company's commitment to advancing the field of ophthalmology and finding new treatments for eye disorders.

Stuart Therapeutics' presence at these upcoming meetings demonstrates their dedication to innovation and their potential to make a significant impact in the field of ophthalmology. With their cutting-edge research and promising results, they are poised to become a leader in developing therapies for anterior segment, refractive, and posterior segment eye disorders.
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • PinnacleQM launches new enterprise website to help Australian organisations deliver more with confidence
  • Tacoma: Statement from District 4 Council Member Sandesh Sadalge and At-Large Council Member Olgy Diaz on Sale of Northwest ICE Processing Center to Federal Government
  • Loud! OOH Launches UK's First Free Planning Tool for UK Outdoor Advertising Budgets
  • Tacoma Creates 2025-2026 Annual Report Demonstrates Continued Investment in Arts, Culture, Heritage, and Science Across Tacoma
  • Boston Industrial Solutions Introduces the New Volta® M100 Pad Printing Machine
  • Not a Black Box Launches TalentOS, the First Talent Harness Operating System
  • City of Tacoma's Adopted Biennial Budget Focuses on Everyday Services and Fiscal Sustainability
  • Spokane: Local Leaders Celebrate Community Redevelopment in East Central
  • A Diwali Celebration with Heritage at South Brunswick Residents & American Properties
  • Law Offices of Larry E. Bray, P.A. Wins Fourth District Appeal Clarifying Limits of Florida's Offer of Judgment Statute
  • Holiday Magic Returns to Downtown Downers Grove November 27-29
  • What If the Greatest Gift This Holiday Season Came in a Dream of Your Loved One in Spirit?
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Minneapolis
  • LGF Lab Gas Flow Launches Fully Automatic Laboratory Gas Changeover Manifold System with Ultra High Purity Gas Regulator Valve
  • Record Q3 Revenue and Gross Profit Delivered: Revenue Surges 40%, Gross Margin Soars to 36% & Adjusted EBITDA Loss Narrows 64% for Cycurion, Inc $CYCU
  • Inaugural 12 Trees of Christmas gala raises $525,000 for DMG research and family support
  • BitTitan Expands MigrationWiz with SharePoint Sites Migration and Simplified Collaboration Licensing
  • Olympic champion Katie Moon to compete at Pole Vault in Paradise in Key West
  • Smith Strong Merges With Gravis Law, Bringing Gravis Law to Virginia
  • Turkish Engineer Who Cracked Wall Street's Algorithm Launches Hermes AI Analyzer
_catLbl0 _catLbl1

Popular on Washingtoner

  • Pre-Seed VC Martin Tobias Makes Fundraising Tool Available to Every Startup CEO as Investor Match - 333
  • New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX) - 297
  • LocalsVoted Launches: Local Rankings From Phone-Verified Votes, Not Paid Placement - 186
  • One in three Americans may have lost track of retirement savings from a previous job - 122
  • Datavalet Named One of Quebec's Best Workplaces™ for 2026 - 118
  • Nextlink Internet Deploys netElastic to Modernize Its Hybrid Broadband Network - 103
  • Tacoma: OMWBE Active Certification Class on November 16 - 103
  • ThriveStack citedby launches Prompt Research to find the prompts buyers ask in AI search
  • Sturtevant's Offers Free Ski and Snowboard Edge-and-Wax Services in Bellevue Oct. 29
  • Paraguay Expedition Offers a Different View of Human Resilience

Similar on Washingtoner

  • Scott Glickson Joins STS Capital Partners as Managing Director
  • BREAKTHROUGH TROP2 Research Reveals New REQORSA® Opportunities as Roche Collaboration Strengthens Precision Lung Cancer Strategy
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Dallas–Fort Worth
  • Loud! OOH Launches UK's First Free Planning Tool for UK Outdoor Advertising Budgets
  • Boston Industrial Solutions Introduces the New Volta® M100 Pad Printing Machine
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Minneapolis
  • Record Q3 Revenue and Gross Profit Delivered: Revenue Surges 40%, Gross Margin Soars to 36% & Adjusted EBITDA Loss Narrows 64% for Cycurion, Inc $CYCU
  • Entrepreneur Nouho M Kanneh Talks Family, Faith and a $37 Million Portfolio in New Interview
  • Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
  • Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
Copyright © 2026 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute